|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0026336,
umls-concept:C0030956,
umls-concept:C0033817,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0038257,
umls-concept:C0041951,
umls-concept:C0084709,
umls-concept:C0205195,
umls-concept:C0250480,
umls-concept:C0442120,
umls-concept:C0443315,
umls-concept:C1136254,
umls-concept:C1292733,
umls-concept:C1522408,
umls-concept:C1522613,
umls-concept:C1553454
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2007-11-23
|
|
pubmed:abstractText |
We investigated the efficacy of Tachyplesin III alone or combined with piperacillin-tazobactam (TZP) to prevent biofilm formation in vitro and in a rat model of Pseudomonas aeruginosa ureteral stent infection. We have observed that in vitro TZP, in presence of Tachyplesin III, showed minimal inhibitory concentrations (MIC)s twofold and minimal bactericidal concentrations (MBC)s eightfold lower. The in vivo study showed that rats that received intraperitoneal TZP showed the lowest bacterial numbers. Tachyplesin III combined with TZP showed efficacies higher than that of each single compound. Coating ureteral stents with Tachyplesin III is able to inhibit bacterial growth up to 1,000 times.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0196-9781
|
|
pubmed:author |
pubmed-author:CirioniOscarO,
pubmed-author:GhiselliRobertoR,
pubmed-author:GiacomettiAndreaA,
pubmed-author:KamyszElzbietaE,
pubmed-author:KamyszWojciechW,
pubmed-author:MinardiDanieleD,
pubmed-author:MuzzonigroGiovanniG,
pubmed-author:OrlandoFiorenzaF,
pubmed-author:ParriGianniG,
pubmed-author:SabaVittorioV,
pubmed-author:ScaliseGiorgioG,
pubmed-author:SilvestriCarmelaC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2293-8
|
|
pubmed:meshHeading |
pubmed-meshheading:18022289-Animals,
pubmed-meshheading:18022289-Anti-Bacterial Agents,
pubmed-meshheading:18022289-Antimicrobial Cationic Peptides,
pubmed-meshheading:18022289-Bacterial Adhesion,
pubmed-meshheading:18022289-Biofilms,
pubmed-meshheading:18022289-Colony Count, Microbial,
pubmed-meshheading:18022289-DNA-Binding Proteins,
pubmed-meshheading:18022289-Disease Models, Animal,
pubmed-meshheading:18022289-Drug-Eluting Stents,
pubmed-meshheading:18022289-Male,
pubmed-meshheading:18022289-Penicillanic Acid,
pubmed-meshheading:18022289-Peptides, Cyclic,
pubmed-meshheading:18022289-Piperacillin,
pubmed-meshheading:18022289-Pseudomonas Infections,
pubmed-meshheading:18022289-Pseudomonas aeruginosa,
pubmed-meshheading:18022289-Rats,
pubmed-meshheading:18022289-Rats, Wistar,
pubmed-meshheading:18022289-Ureteral Diseases
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model.
|
|
pubmed:affiliation |
Institute of Maternal and Children's Sciences-Urology, Polytechnic University of the Marche Region, A.O. Ospedali Riuniti, 60020 Ancona, Italy. d.minardi@univpm.it
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
